

Market snapshot

al

Equities - India	Close	Chg .%	YTD.%
Sensex	32,242	0.2	21.1
Nifty-50	10,087	0.1	23.2
Nifty-M 100	18,936	0.6	31.9
Equities-Global	Close	Chg .%	YTD.%
S&P 500	2,496	-0.1	11.5
Nasdaq	6,429	-0.5	19.4
FTSE 100	7,295	-1.1	2.1
DAX	12,540	-0.1	9.2
Hang Seng	11,101	-0.8	18.2
Nikkei 225	19,807	-0.3	3.6
Commodities	Close	Chg .%	YTD.%
Brent (US\$/Bbl)	55	0.3	-0.6
Gold (\$/OZ)	1,325	-0.7	14.3
Cu (US\$/MT)	6,456	-0.9	16.9
Almn (US\$/MT)	2,068	-0.5	21.4
Currency	Close	Chg .%	YTD.%
USD/INR	64.1	0.1	-5.6
USD/EUR	1.2	-0.7	12.8
USD/JPY	110.4	0.3	-5.7
YIELD (%)	Close	1MChg	YTDchg
10 Yrs G-Sec	6.6	0.0	0.1
10 Yrs AAA Corp	7.5	0.0	0.0
Flows (USD b)	14-Sep	MTD	YTD
FIIs	-0.1	-0.5	6.3
DIIs	0.1	0.9	7.4
Volumes (INRb)	14-Sep	MTD*	YTD*
Cash	311	303	290
F&O	10,031	5,533	5,306
Noto: VTD is calon	darvoar *	Ava.	

Note: YTD is calendar year, *Avg

Today's top research theme

Fund Folio: AUM scales new highs; global cyclicals see buying

- ✓ Domestic mutual fund industry equity AUM rose for the ninth consecutive month in August to scale a new high of INR6.4t (+2.3% MoM and +37% CY17 YTD).
- ✓ The increase in equity AUM was led by a rise in equity scheme sales to INR325b (+16% MoM) and a fall in redemptions by 21% MoM to INR121b (as market indices were down; Nifty -1.6% MoM), leading to a rise in net inflows (INR204b, +60% MoM). Notably, net inflows of INR204b in August were the highest-ever in a month.
- ✓ In August, 982k new SIP accounts were added, taking the total SIP accounts to 15.9m. The total amount collected through SIP during the month of August was INR52.1b, up ~50% YoY.
- ✓ The month saw a notable change in sector and stock allocation of funds. Weight of Global Cyclicals is now in double-digits (10.5%, +90bp MoM). Defensives' weight too increased by 30bp to 23.7%, led by a rise in the weight of Utilities (+40bp to 3.4%). Domestic cyclicals' weight fell by 120bp to 65.8% due to a decline in the weights of Banks (PVT and PSU), Autos, Capital Goods and Infrastructure, partly offset by a small increase in the weight of NBFCs.

Research covered

Cos/Sector	Key Highlights
Fund Folio	Sep-17: Indian Mutual Fund Tracker — AUM scales new highs
EcoScope	August inflation doesn't dampen case for rate cut
Real Estate Day	Turning toward a new paradigm

Piping hot news

SEBI may probe Shree Cement, NBI promoters over allegations of defraud

✓ Promoters of NBI Industrial Finance, a stakeholder in one of North India's leading cement company Shree Cement, may be examined by SEBI on allegations of defrauding minority shareholders.




Chart of the Day: Sector allocation of domestic MFs – weights of Global Cyclicals increased, while those of Domestic Cyclicals' saw signs of moderation

Weight of Global Cyclicals is now in double-digits (10.5%, +90bp MoM)





Domestic cyclicals' weight fell by 120bp to 65.8%



Research Team (Gautam.Duggad@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report. Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.



Tata Sons plans to go private limited

In notice to its shareholders ahead of the annual general meeting (AGM) scheduled for September 21, Tata Sons has sought approval to amend its memorandum of association and articles of association to convert itself from a public limited company to a private limited one...

In the news today

Kindly click on textbox for the detailed news link



North Korea fires missile over Japan, UNSC convenes emergency meeting

North Korea fired an unidentified missile eastwards over Japan on Friday, Seoul and Tokyo said. The launch, from near Pyongyang, came after the United Nations Security Council imposed an eighth set of sanctions on the country over its banned missile and nuclear programmes. That was in response to its sixth nuclear test- by far its largest yet- earlier this month, which Pyongyang said was a hydrogen bomb small enough to fit onto a missile...

3

Maruti gets electric boost as Suzuki vows to produce lithium ion batteries by 2020 Japanese automaker Suzuki Motor Corp. on Thursday said that its joint venture partnership with Toshiba Corp. and Denso Corp. will start making lithium ion batteries for India and international markets from 2020...

4

Idea tells Trai to fix IUC by separating VoLTE, other networks

Giving a fresh twist to the ongoing tussle over interconnect usage charges (IUC), Idea Cellular Ltd on Thursday wrote to the telecom regulator asking it to evaluate IUC by bifurcating the calls terminating on VoLTE networks (where Jio has a huge presence) and those terminating on...

6

'Utilities to get ₹6,000 cr. relief due to GST on coal'

Changes in the tax structure on coal following the introduction of GST would translate to a ₹6,000 crore relief to the power sector, a senior Coal India Ltd. (CIL) official told shareholders on Thursday...



Idea, Vodafone mobile tower assets draw interest from ATC, Brookfield, IDFC Alternatives American Tower Corp. (ATC), Brookfield Asset Management and IDFC Alternatives have emerged as the front runners for the independent tower assets of

Vodafone India and Idea Cellular Ltd in a combined transaction, according to two people with direct knowledge of the development...

5

Govt invites bids to appoint banks, lawyer for Air India sale The government has invited bids to appoint two financial advisors and one legal advisor for the privatisation of national carrier Air India and its subsidiaries, the Ministry of Finance said in a newspaper advertisement on Thursday...




Database Periodical | 14 September 2017 Fund Folio Indian Mutual Fund Tracker

AUM scales new highs; global cyclicals see buying

- Equity AUM rose for the ninth consecutive month in August to scale a new high of INR6.4t (+2.3% MoM and +37% CY17 YTD).
- n The increase in equity AUM was led by a rise in equity scheme sales to INR325b (+16% MoM) and a fall in redemptions by 21% MoM to INR121b (as market indices were down; Nifty -1.6% MoM), leading to a rise in net inflows (INR204b, +60% MoM).
- n Falling interest rates on bank deposits and dimming appeal of traditional asset classes like real estate and gold are the key reasons for huge inflows in mutual funds. Notably, net inflows of INR204b in August were the highest-ever in a month.
- n Total net inflows of the MF industry in CY17 YTD stand at INR2,478b, two thirds of which are contributed by equity funds and income schemes. All categories of funds, except GILT, gold ETFs and FOF, have witnessed positive inflows.
- n In August, 982k new SIP accounts were added, taking the total SIP accounts to 15.9m. The total amount collected through SIP during the month of August was INR52.1b, up ~50% YoY.

Some interesting facts

- n The month saw a notable change in sector and stock allocation of funds. Weight of Global Cyclicals is now in double-digits (10.5%, +90bp MoM). This was mainly driven by an increase in the weights of Oil & Gas (+60bp to 6.7%) and Metals (+30bp to 3.8%). Defensives' weight too increased by 30bp to 23.7%, led by a rise in the weight of Utilities (+40bp to 3.4%).
- Domestic cyclicals' weight fell by 120bp to 65.8% due to a decline in the weights of Banks (PVT and PSU), Autos, Capital Goods and Infrastructure, partly offset by a small increase in the weight of NBFCs.
- n Of the top 10 stocks in terms of value increase MoM, four were from Oil & Gas.
- n All three OMCs were preferred by MFs in August; IoCL, HPCL and BPCL witnessed net buying by 13, 14 and 12 funds, respectively. Value of IOCL increased by INR15b, HPCL by INR13b and BPCL by INR6.6b. Stock prices of IOCL, HPCL and BPCL were up by 24%, 27% and 12%, respectively.
- GAIL India was also one of the preferred stocks in oil & gas among MFs in August, with net buying by 12 funds.
 Value increased by INR6.4b, despite the stock remaining flat during the month.
- Value shocks were seen in banking stocks. SBI saw a decline of INR27.4b in value; 10 funds sold the stock (it was down by 11% for the month). Other banks witnessing an decrease in value on an MoM basis were BoB (INR7.5b), Kotak Mahindra Bank (INR5.5b) and Federal Bank (INR3.1b).



Flows: Net inflows in August at INR204b - highest-ever in a month

 Mutual funds' gross inflows rose to INR325b (+16% MoM) in August. Also, there was a meaningful fall in redemptions to INR121b (-21% YoY), leading to a 60% increase in net inflows to INR204b in August from INR127b in July.




Exhibit 3: Monthly trend of sales, redemptions and net amount raised by mutual funds (toward equity)

Exhibit 4: Yearly trend of net inflows by mutual funds (toward equity)





Exhibit 5: Yearly trend of sales and redemptions by mutual funds (toward equity)



Sector-wise weight: MoM increase seen in Oil & Gas, Utilities and Metals

- In August, MFs showed interest in Oil & Gas, Utilities, Metals, NBFCs, Consumer and Retail-these sectors saw n an MoM increase in weight. Banks (PSU and Private), Autos, Capital Goods, Technology, Healthcare and Infrastructure saw an MoM decrease in weight.
- Private Banks (17.4%) had the top sector holding in August, followed by Auto (9.7%), Capital Goods (8.1%) and n NBFC (8.1%).
- PSU Banks and Infrastructure were the top sectors witnessing a decline in value on an MoM basis. n




Exhibit 6: Sector allocation (%): Financials and Metals see highest increase





August inflation doesn't dampen case for rate cut

Monetary policy support necessary to revive weak economic activity

- n With India's retail inflation more than doubling from 1.5% YoY in June 2017 to 3.4% YoY in August 2017, it is broadly believed that the rate cut window has probably closed. However, details of CPI reveal that the entire rise in headline inflation is driven by three items vegetables, fuel for vehicles, and housing. Excluding these, inflation in August was the same as in June 2017 at 2.7%.
- **n** The uptick in these three items can be attributed to seasonal, global developments, and statistical effects, respectively, rather than any structural bias. Consequently, they should be avoided in policy-making considerations.
- n Meanwhile, economic growth has visibly weakened, which is likely to be reflected in RBI's revised forecasts next month. Private investments need desperate policy support and ~90% of the economy grew sub-4.5% for the second consecutive quarter in 1QFY18. Accordingly, we believe that recent inflation readings don't dampen the case for rate cuts. In fact, weaker-than-expected economic activity needs monetary policy support, as <u>fiscal push is unlikely</u>.

Higher headline inflation in the past two months was entirely driven vegetables, fuel for vehicles, and housing; inflation in more than 80% of the CPI basket in August was the same as in June 2017 at 2.7%

> Excluding fuel for vehicles, inflation in miscellaneous group was 3.4% YoY in August 2017, similar to 3.3% in June/July 2017

Higher headline CPI overshadows extremely comfortable details

For the second consecutive month, headline CPI inflation increased by almost a full percentage point, rising from 1.46% YoY in June 2017 to 2.36% in July and 3.36% in August 2017. Higher-than-expected headline inflation has led to trimming of rate cut expectations. We, however, have not done so. This is because the RBI ignores movements in headline indices related to statistical changes or one-off events. Unless the changing trend represents structural bias, the RBI maintains its forecasts. The last two months' inflation data need close scrutiny by members of the Monetary Policy Committee (MPC) because headline data overshadow favorable details.

We have four key findings in this report, which, we believe, must be considered by the RBI before its policy decision on October 4, 2017.

- Higher headline inflation in the past two months was entirely driven by three components – vegetables (6.04%), fuel for vehicles (2.36%) and housing (10.07%), weighing 18.5% of the CPI basket. Inflation in more than 80% of the CPI basket in August was the same as in June at 2.7%.
- While inflation in miscellaneous group (weight: 28.3%) picked up sharply from 3.3% YoY in June/July 2017 to 3.8% in August, it was entirely driven by fuel for vehicles (petrol, diesel & other fuels). Excluding such fuel items (weight: 2.36%), inflation in miscellaneous group was 3.4% YoY in August 2017, similar to 3.3% in June/July 2017.
- 3. Since petrol & diesel were the key culprits for higher inflation in miscellaneous group, it is inappropriate to argue that GST is inflationary. In fact, inflation in 'core services' (weight: 12.5%) was 3.9% YoY in August 2017, only marginally higher than 3.6% in June.
- 4. Finally, as expected, while the revisions in housing rent allowance (HRA) led to a slight pick-up in housing index, the uptick is trivial to have any meaningful second-round impact.



Real Estate Day

Real Estate Day: Turning toward a New Paradigm

The Indian real estate sector was at its peak roughly a decade ago. Demand was genuine, interest rates were low and the sector was opened up for foreign direct investment (FDI). However, post the global financial crisis in 2008, transparency and consumer confidence began dwindling, straining the real estate industry. The situation has turned more worrisome over the past 3-4 years.

However, the recent introduction of the Real Estate (Regulation and Development) Act, 2016 has pumped in a new lease of life into the sector. It is expected to weed out unorganized players from the industry and whip up buyer confidence, bringing back the much-needed buoyancy.

Real estate per se is not much known for governance, and thus, has not been a preferred destination for investments. However, the big-bang measures by the Indian government (such as demonetization and GST) are expected to drive formalization of the economy, reinstating investor confidence.

Against this promising backdrop, we hosted 'Real Estate Day', which saw participation of many stakeholders from the real estate industry. We met with (a) two experts managing PE Real Estate Funds, (b) an owner of a premium real estate company and (c) CEO of one of India's largest real estate consultants, to take stock of their view about the real estate industry, the ground realty, and the impact of RERA. Key takeaways from their presentations:

- RERA is expected to determine the future of India's real estate sector. The stringent compliance norms under this act will likely result in consolidation to the extent of 30-40% in this industry. Most small players would thus find it difficult to survive, with business largely shifting in favor of organized players.
- n The recent changes in the REIT rules are attracting investor attention; expect India's first REIT to be listed by year-end.
- n Residential prices have been stagnant for the past 3-4 years, and the coming few years too should not see much exuberance. However, a few organized names are expected to take a significant slice of the pie due to consolidation in the sector.
- n In metro cities, vacancies in the commercial segment at are at all-time low, which once absorbed, should lead to increase in rentals. Vacancy in commercial malls overall is high, but Grade A malls are much better placed.





1. Movement in domestic oil prices is as per movement in international oil prices: HPCL; MK Surana, CMD

- Saw an impact on crude price due to natural calamities. Company is aligned to international oil prices. So movement in domestic oil prices is as per movement in international oil prices.
- **n** Company making marketing margin of Rs. 1.5 2 per litre currently.
- n Company has to incur all expenses when operating petrol pumps.
- Dealer commissions have changed, international prices are impacting domestic prices. Have seen an increase in the cost of operating pumps.
- n Not the right person to comment on the taxation of petrol and diesel.

🔿 Read More

2. See more international orders than domestic; to better topline in FY18: Thermax; MS Unnikrishnan, MD

- Expect better order intake for the entire year Q1 was good and expect Q2 to be better than last year Q2.
- Have seen a surge in finalization of contracts globally and domestically. Lot of finalization of contracts post GST implementation but cannot confirm of a turnaround yet.
- n So far order intake has been more on international side than domestic. In India, order ticket size has been small so far.
- Traction in orders in India have been seen in food industry, beverages, automobile and auto ancillary, pharma companies, light engineering – spaces that are consumption oriented.
- Hopeful of doing better in topline and profits for FY18 than FY17. Although margins under pressure, focus on stabilizing the same through better cost management.

Read More


3. Scenario on Indian agriculture is depressing: Godrej International; Dorab Mistry, Director

- n Last year a disgrace for agriculture.
- n Monsoon not well spaced out and plentiful this year compared to last year.
- n Scenario on Indian agriculture depressing.
- n Rural economy is the foundation of country's economy which is why it is so important to remunerate farmers better.
- **n** Government has two alternatives, either raise import duty or allow productivity to be raised.

Read More

4. Expect growth of 25% in FY18: MIRC Electronics; Vijay Mansukhani, MD

- n Looking to monetize non-core assets worth Rs. 200 crore.
- n Company will become debt free after demonetizing non-core assets.
- n Expect growth of 25% in FY18.
- n Current debt around Rs. 130 crore.



n



1. Why inclusive growth is indispensable to India

On 15 August India marked 70 years of independence from the British empire, a monumental triumph in social and political liberalization. Today, India is in the midst of an equally monumental struggle in economic liberalization. The stakes could not be higher. An economic future of broadly shared prosperity and vanishing poverty for more than 1.2 billion people is within grasp. To get there, however, calls for advancing inclusive growth. India's economic performance in recent years has been outstanding in relation to both its own historical record and the global economy. Between 2010 and 2016, for example, annual real gross domestic product (GDP) growth in India averaged 6.7% despite a relatively weak post-crisis global economy that averaged only 2.7% annual gains. Yet the economic optimism in recent years is now tempered by a growing recognition that many deficiencies in the economy remain deep-seated and if not effectively addressed could undermine future growth. Front and centre is the concern over employment growth.

Read More

2. Is bad advice driving India's irrepressible bulls?

India's economy is not doing as well as many had hoped. Growth has been slowing for several quarters, and even if there's a slight recovery in coming quarters, the signs for the medium term aren't propitious. There appears to be no end in sight to a slow-moving banking crisis. And private investment has crashed, reflecting pessimism at Indian businesses about the future and possible returns. India's government looks less and less likely to carry out the kind of deep reform that the country's economy needs, while its inexplicable decision to withdraw 86% of the country's cash overnight—a decision that was as badly implemented as it was poorly conceived—has gravely damaged Prime Minister Narendra Modi's reputation as a manager of the economy. So the question is: Why aren't these facts, which are easy to ascertain, reflected in the giddy statements regularly made about the Indian economy, especially by analysts and advisers to global investors?



3. Assessing the 25 billion digital payments target

The government of Prime Minister Narendra Modi has made two big bets on digital payments. Some weeks after demonetisation, government representatives began to extol the virtues of digital payments as a means to increasing economic transparency, formalizing the economy, and widening the tax base. As outcomes have shown, this was a sober recalibration of the objectives of demonetization. And earlier this year, the government announced the "DigiDhan Mission" to achieve a 25 billion digital transactions target, outlined in the Union budget for this fiscal. This programme aims to establish a robust digital payments ecosystem in a potentially transformative attempt to drain the swamp of illicit monetary transactions. As we approach the completion of the second quarter of this fiscal, it is important to take stock of achievements against this target.



4. Restructure, not cap, CEO remuneration

n CEOs of some well-known blue-chip Indian companies are reportedly yet to receive their revised compensation packages. This is baffling. The government must ensure speedy passage of the amendments to the Companies Act in the Rajya Sabha to end their three-year wait. It should also remove the caps on managerial remuneration. Instead of caps, corporate regulation should ensure sound functioning of the board, and transparent accounting to prevent managerial remuneration being disguised as company expenditure. The most important part is making senior management remuneration reflect their contribution to corporate performance. The bulk of the remuneration of a CEO, whose performance has a material impact on the company's performance, should be a variable component. This automatically means low, fixed compensation. The variable component should be deferred for at least three to four years and the payout mostly linked to the company stocks.

🔿 Read More 🕽

International

5. Merkel's message to Theresa may: Brexit means Brexit

n Britain wants to pick up the pace. EU negotiators in Brussels are taking their time. Blackmail and sabotage, cry Westminster's Brexiters. The explanation is more prosaic. The more urgent a deal begins to seem for Britain, the higher the incentives stack in favour of a stalling strategy from the EU27. This, of course, is how the process was designed. Article 50 of the union's treaty was written to discourage nations from leaving. As soon as Theresa May set the article's two-year clock ticking in March, she conceded the advantage to those sitting on the other side of the table. The prime minister was warned of the danger by her advisers. But that was before she had lost an election and Britain had to confront the hard reality that it cannot have its cake and eat it.

Read More



Click excel icon for detailed valuation guide

Valuation snapshot

		CMP	TP	% Upside		EPS (INF	2)	P/E	E (x)	P/	B (x)		ROE (%)	
Company	Reco	(INR)	(INR)	Downside	FY17	FY18E	FY19E	FY17	FY18E	FY17	FY18E	FY17	FY18E	FY19E
Automobiles														
Amara Raja	Buy	785	986	26	28.0	28.2	37.9	28.0	27.8	5.2	4.5	20.3	17.3	19.9
Ashok Ley.	Buy	117	118	1	4.6	5.2	7.0	25.8	22.7	5.6	5.0	23.1	23.2	27.0
Bajaj Auto	Buy	2,929	3,281	12	132.3	137.2	163.6	22.1	21.3	5.0	4.5	25.3	22.2	24.0
Bharat Forge	Buy	1,259	1,353	7	26.2	36.5	50.5	48.1	34.5	7.1	6.2	16.2	19.2	22.8
Bosch	Neutral	21,976	21,994	0	473.1	547.2	705.7	46.4	40.2	7.6	6.9	15.8	18.0	20.7
CEAT	Buy	1,764	2,029	15	93.3	94.2	126.8	18.9	18.7	3.0	2.6	16.9	14.8	17.3
Eicher Mot.	Buy	32,059	35,854	12	612.7	852.9	1,092.8	52.3	37.6	16.3	12.1	37.1	37.0	35.4
Endurance Tech.	Buy	1,013	1,059	5	23.5	29.3	37.9	43.2	34.6	8.2	6.8	20.8	21.6	23.3
Escorts	Neutral	671	732	9	20.0	37.1	45.8	33.6	18.1	3.4	2.9	10.6	17.3	18.3
Exide Ind	Buy	220	269	22	8.1	9.2	11.0	27.1	24.0	3.8	3.4	13.9	14.1	15.0
Hero Moto	Neutral	3,895	3,818	-2	169.1	189.3	199.1	23.0	20.6	7.7	6.6	35.7	34.6	31.5
M&M	Buy	1,291	1,625	26	54.3	68.5	82.4	23.8	18.8	3.0	2.7	14.2	13.9	14.9
Mahindra CIE	Not Rated	241	-		5.4	9.9	11.8	45.0	24.4	2.8	2.5	6.4	10.8	11.5
Maruti Suzuki	Buy	8,071	8,819	9	248.6	281.7	374.5	32.5	28.7	6.7	5.9	20.3	20.1	22.8
Tata Motors	Buy	404	542	34	19.8	22.4	59.8	20.4	18.0	2.4	2.1	9.8	12.3	26.6
TVS Motor	Buy	641	612	-5	11.7	14.4	23.7	54.6	44.5	12.6	10.4	25.6	25.7	33.6
Aggregate	54,	511	512	0	/		20.7	29.0	25.0	4.9	4.3	17.1	17.4	22.3
Banks - Private								27.0	20.0	т.7	4.5	17.1	17.4	22.5
Axis Bank	Neutral	520	545	5	15.4	21.8	38.1	33.8	23.8	2.3	2.1	6.9	9.3	14.7
DCB Bank	Neutral	190	192	1	7.0	8.4	10.4	27.1	23.0	2.8	2.3	10.8	11.4	11.8
Equitas Hold.	Buy	164	201	22	5.0	1.7	6.1	32.6	95.0	2.5	2.3	9.5	2.6	8.7
Federal Bank	Buy	115	139	22	4.8	5.4	6.8	23.8	21.3	2.3	1.8	9.9	10.0	10.5
HDFC Bank		1,843	2,000	9	56.8	68.2	82.1	32.5	27.0	5.5	4.7	18.3	18.8	19.6
ICICI Bank	Buy	294	366	25	15.3	14.9	17.0	32.5 19.2	19.7	2.2	2.0	10.3	8.9	9.5
IDFC Bank	Buy Neutral	61	62	25	2.3	2.8	3.2	26.0	21.9	1.4	1.3	5.6	6.3	6.9
			- 02	Z	47.9	61.9	76.8			5.2	4.5	15.4		18.5
IndusInd	Under Review	1,727		11				36.0	27.9				17.3	
J&K Bank	Neutral	80	91	14	-31.3	3.8	8.2	NM	20.8	0.7	0.7	-27.0	3.5	7.2
Kotak Mah. Bk	Buy Hadaa Daview	1,008	1,153	14	26.8	32.4	41.0	37.5	31.1	4.9	4.3	13.8	15.0	16.3
RBL Bank	Under Review	532	-	10	11.9	18.0	23.7	44.8	29.5	4.7	3.3	12.3	13.6	13.9
South Indian	Buy	29	34	19	2.2	2.9	3.7	13.2	10.0	1.1	1.0	9.5	10.8	12.7
Yes Bank	Buy	1,852	2,133	15	73.0	92.3	114.5	25.4	20.1	4.0	3.4	18.9	18.3	19.5
Aggregate								30.5	24.6	3.5	3.1	11.5	12.5	14.2
Banks - PSU			4.0.0						45.0					
BOB	Buy	146	198	36	6.0	9.5	20.8	24.4	15.3	1.0	0.9	4.0	6.1	12.4
BOI	Neutral	153	149	-3	-14.8	-11.2	6.6	NM	NM	0.7	0.7	-6.7	-5.2	3.0
Canara	Neutral	346	360	4	18.8	30.1	47.0	18.4	11.5	0.7	0.7	4.2	6.2	9.1
IDBI Bk	Neutral	57	49	-13	1.5	6.4	8.6	36.9	8.8	0.5	0.5	1.4	5.8	7.3
Indian Bk	Buy	284	382	34	29.3	34.4	38.3	9.7	8.3	0.9	0.9	10.1	10.9	11.2
OBC	Neutral	133	150	13	-31.6	17.1	21.4	NM	7.8	0.4	0.3	-8.4	4.6	5.4
PNB	Buy	145	184	27	6.2	5.8	11.0	23.3	24.9	0.8	0.8	3.6	3.2	5.9
SBI	Buy	274	341	24	0.3	14.6	26.8	920.8	18.8	1.3	1.2	-0.2	7.0	11.4
Union Bk	Neutral	138	140	2	8.1	9.0	19.1	17.0	15.2	0.4	0.5	2.7	3.0	6.1
Aggregate								100.2	17.8	0.9	0.8	0.9	4.6	8.3
NBFCs														
Bajaj Fin.	Buy	1,914	1,800	-6	33.6	47.6	62.9	57.0	40.2	10.9	8.9	21.7	24.3	25.9
Bharat Fin.	Neutral	955	820	-14	21.0	31.8	68.7	45.5	30.0	5.4	4.4	15.1	16.1	28.0
Capital First	Buy	802	925	15	24.6	33.3	44.3	32.5	24.1	3.4	3.0	12.0	13.3	15.6
Cholaman.Inv.&Fn	Buy	1,178	1,400	19	46.0	56.0	67.3	25.6	21.0	4.3	3.6	18.0	18.6	19.0
Dewan Hsg.	Buy	561	630	12	29.6	37.7	47.1	18.9	14.9	2.2	2.0	14.4	14.1	15.6
GRUH Fin.	Neutral	536	450	-16	8.1	9.9	12.1	65.9	53.9	19.7	16.2	32.5	33.0	32.8
HDFC	Buy	1,771	1,900	7	46.8	52.9	59.0	37.8	33.5	7.0	6.3	18.9	19.3	18.4
Indiabulls Hsg	Buy	1,267	1,350	7	69.0	86.3	108.4	18.4	14.7	4.4	3.9	25.5	28.2	31.3
L&T Fin Holdings	Buy	201	200	-1	5.2	7.3	10.6	38.5	27.5	4.5	4.0	12.4	15.6	19.1
LIC Hsg Fin	Neutral	660	708	7	38.2	41.6	48.9	17.3	15.9	3.1	2.7	19.4	18.2	18.5
Lionsynn	Noutin	000	100	,	50.Z	11.0	10.7	17.5	10.7	5.1	2.1	17.4	10.2	10.0

		CMP	TP	% Upside		EPS (INF	2)	P/E	E (x)	P/	B (x)		ROE (%))
Company	Reco	(INR)	(INR)	Downside	FY17	FY18E	FY19E	FY17	FY18E	FY17	FY18E	FY17	FY18E	FY19E
Manappuram	Not Rated	109	-		8.6	10.8	12.5	12.6	10.1	2.8	2.5	24.0	25.9	26.9
M&M Fin.	Buy	434	459	6	7.1	13.9	17.8	61.3	31.3	3.9	3.6	6.5	12.0	14.2
Muthoot Fin	Buy	508	550	8	29.5	38.2	44.2	17.2	13.3	3.1	2.6	19.4	21.5	21.2
PFC	Neutral	131	117	-11	25.7	27.2	30.2	5.1	4.8	0.9	0.8	17.9	17.0	16.8
Repco Home	Buy	669	800	20	29.1	34.5	39.3	23.0	19.4	3.7	3.1	17.4	17.5	17.0
REC	Neutral	169	134	-21	31.4	35.0	40.4	5.4	4.8	1.0	0.9	19.9	19.1	19.1
Shriram City Unior	n Buy	2,061	2,800	36	84.3	121.7	164.1	24.4	16.9	2.7	2.4	11.7	15.0	17.6
STF	Buy	1,077	1,330	24	55.6	80.0	102.4	19.4	13.5	2.2	1.9	11.7	15.0	16.9
Aggregate	,	•	· ·					21.6	18.1	3.6	3.2	16.8	17.6	18.1
Capital Goods														
ABB	Sell	1,423	1,200	-16	19.7	22.4	31.6	72.2	63.5	9.2	8.0	12.7	12.6	15.8
Bharat Elec.	Buy	190	215	13	6.9	7.4	8.2	27.5	25.7	5.7	4.4	20.6	17.0	16.9
BHEL	Sell	137	100	-27	2.1	4.6	4.9	63.9	30.1	1.0	1.0	1.6	3.4	3.5
Blue Star	Neutral	779	650	-17	12.9	17.5	26.1	60.5	44.5	9.8	9.2	18.0	21.4	29.6
CG Cons. Elec.	Buy	219	250	14	4.7	5.0	6.4	46.8	43.5	25.5	18.8	76.4	49.7	49.7
CG Power & Indu.	Neutral	85	80	-6	4.1	2.0	2.5	20.7	41.8	1.3	1.2	6.2	3.0	3.7
Cummins	Buy	944	1,180	25	26.5	27.7	35.0	35.6	34.1	7.0	6.5	21.2	19.7	22.8
GE T&D	Neutral	401	395	-2	5.7	9.3	11.3	70.0	43.2	9.9	8.7	12.4	21.5	22.0
Havells	Neutral	505	455	-10	9.6	10.9	13.8	52.8	45.2	9.9	8.6	12.4	18.6	22.7
K E C Intl	Neutral	330	295	-10	9.0	13.1	16.4	27.8	25.3	5.3	4.6	21.2	19.5	20.7
L&T	Buy	1,215	1,380	-11	42.3	46.5	56.2	27.8	26.1	3.4	3.1	12.5	19.5	13.8
	Not Rated	1,215		14	42.3		11.2	15.7						
Pennar Eng.			-	2		9.1			12.2	1.6	1.4	10.2	11.6	12.6
Siemens	Neutral	1,384	1,355	-2	17.8	22.7	33.0	77.7	61.0	7.2	6.3	9.3	10.3	13.7
Solar Ind	Neutral	930	900	-3	20.6	24.2	30.0	45.1	38.4	8.3	7.1	19.8	19.8	20.9
Suzion Energy	Not Rated	17	-		0.6	0.9	1.0	27.0	19.4	-1.6	-1.7	NM	-8.8	-11.0
Thermax	Neutral	965	830	-14	30.8	30.0	33.2	31.3	32.1	4.3	3.9	14.3	12.7	12.8
Va Tech Wab.	Buy	632	800	27	29.8	34.6	39.8	21.2	18.3	3.5	3.0	16.8	17.6	17.4
Voltas	Sell	544	430	-21	15.5	16.8	19.1	35.2	32.4	5.4	4.8	18.0	15.8	16.0
Aggregate								36.3	31.6	4.1	3.7	11.2	11.7	12.9
Cement	<u> </u>					7.0			40.0			5.4	7.0	
Ambuja Cem.	Buy	284	308	8	4.9	7.0	8.2	58.2	40.9	2.9	2.8	5.1	7.0	7.9
ACC	Neutral	1,844	1,622	-12	36.1	49.8	65.0	51.1	37.0	4.0	3.8	7.9	10.6	13.1
Birla Corp.	Buy	943	1,150	22	29.4	40.9	58.9	32.1	23.0	2.2	2.1	7.3	9.2	12.2
Dalmia Bharat	Buy	2,791	3,282	18	38.8	68.7	89.9	72.0	40.6	5.0	4.5	7.2	11.6	13.4
Grasim Inds.	Neutral	1,232	1,276	4	67.9	71.3	102.7	18.2	17.3	2.0	1.8	11.5	10.9	13.9
India Cem	Neutral	196	201	2	5.6	8.0	11.8	34.9	24.5	1.2	1.1	3.4	4.7	6.6
J K Cements	Buy	1,036	1,277	23	33.7	39.7	54.4	30.7	26.1	4.1	3.6	14.4	14.8	17.5
JK Lakshmi Ce	Buy	425	519	22	7.0	9.7	16.4	61.1	43.7	3.6	3.3	6.0	7.9	12.1
Ramco Cem	Buy	753	806	7	27.3	27.4	34.4	27.6	27.5	4.8	4.2	19.0	16.1	17.5
Orient Cem	Buy	160	185	15	-1.6	4.4	7.1	NM	36.3	3.3	3.1	-3.2	8.8	12.8
Prism Cem	Buy	109	140	29	0.3	3.5	5.6	397.8	31.2	5.7	5.0	1.4	17.0	22.9
Shree Cem	Buy	18,849	22,360	19	384.4	460.4	547.8	49.0	40.9	8.5	7.2	18.4	19.1	19.1
Ultratech	Buy	4,202	4,936	17	96.1	91.5	138.8	43.7	45.9	4.8	4.5	11.6	10.1	14.0
Aggregate								38.7	33.1	3.7	3.4	9.6	10.3	12.7
Consumer														
Asian Paints	Neutral	1,245	1,200	-4	21.0	22.2	26.5	59.2	56.1	15.7	14.3	28.5	26.7	28.1
Britannia	Buy	4,342	4,660	7	73.7	85.3	104.6	58.9	50.9	19.3	15.9	36.9	34.3	34.5
Colgate	Buy	1,141	1,285	13	21.2	24.4	29.8	53.7	46.7	24.4	23.1	50.4	50.8	58.2
Dabur	Neutral	308	315	2	7.2	7.7	9.1	42.5	39.8	11.2	9.6	28.4	26.0	26.3
Emami	Buy	1,141	1,310	15	26.5	26.9	33.1	43.0	42.4	14.8	12.6	35.8	32.0	33.9
Godrej Cons.	Neutral	937	995	6	18.9	21.5	24.7	49.6	43.5	12.0	9.4	24.6	24.2	22.8
GSK Cons.	Sell	5,090	4,500	-12	156.1	158.1	182.1	32.6	32.2	6.9	6.7	22.2	21.1	22.6
HUL	Buy	1,247	1,360	9	19.6	22.9	27.3	63.5	54.3	40.5	39.0	65.6	73.1	82.8
ITC	Neutral	272	280	3	8.4	9.3	10.3	32.4	29.3	7.3	7.2	23.5	24.8	26.3
Jyothy Lab	Neutral	412	395	-4	11.2	9.8	11.1	36.7	41.9	6.9	6.9	21.1	16.5	18.4
	Noutral	712	575	-4	11.2	7.0	11.1	30.7	דו.7	0.7	0.7	۲.۱	10.0	10.4

Company Reco (MN) Downsdel FV1 P FV18 FV17 FV18			СМР	ТР	% Upside		EPS (INF	<u></u> ()	P/F	E (x)	P/	B (x)		ROE (%))
Nextle Nextle1 7.253 6.160 -15 118.0 115.1 132.6 61.0 23.2 24.2 30.0 35.5 28.2 Parge Inik Ruvurta1 8.378 10.60 23.8.7 29.4.7 39.8.4 78.7 63.8 31.5 25.2 40.0 39.6 43.8 Parge Inik Neutra1 83.8 810 -3 16.7 18.1 20.6 50.1 27.0 35.5 35.6 43.8 32.7 28.8 49.9 42.7 Pathend Inderw Neutra1 78.4 87.5 12.8 7.1 11.1 15.0 90.2 77.9 90.8 22.7 18.0 <th>Company</th> <th>Reco</th> <th>(INR)</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>FY17</th> <th></th> <th>FY19E</th>	Company	Reco	(INR)										FY17		FY19E
Page Inds Buy 18,789 19,600 4 28.7 29.47 98.4 78.7 63.8 31.5 25.2 40.0 98.6 27.3 32.2 28.8 40.0 98.6 27.3 32.2 28.8 40.0 98.6 27.5 28.9 12.5 68.9 27.3 32.0 12.6 27.5 28.3 13.0 10.6 28.2 27.5 28.3 Pack Haginen Neutral 8.393 8.00 5 13.2 15.1 17.0 63.3 17.0 18.8 29.2 28.2 29.1 21.4 17.0 18.0 20. 29.2	Marico	Neutral	331	355	7	6.3	6.8	8.2	52.7	48.6	18.4	15.8	36.7	34.9	37.7
Paragnetikt Neutral 249 245 -1 3.6 9.1 12.5 6.89 7.3 3.2.8 6.0 11.0 13. Pidlitteind. Neutral 838 810 3 16.7 18.1 20.6 50.1 46.4 13.0 16.6 39.5 32.8 39.7 32.8 39.7 32.8 39.7 32.8 39.7 32.8 39.7 32.8 39.7 32.8 39.7 32.8 39.7 32.8 49.7 32.7 32.8 49.7	Nestle	Neutral	7,253	6,160	-15	118.0	115.1	133.6	61.5	63.0	23.2	21.6	39.0	35.5	38.1
Pidilie ind. Neutral 88 810 -3 16.7 18.1 20.6 50.1 44.4 130 10.6 28.2 28.2 28.2 28.3 39.3 64.9 62. PK6 Hyginen Not Rated 133 - 3.5 3.5 6.4 76.6 38.2 1.9 1.8 5.2 4.9 8.2 United Brew Neutral 724 8.75 1.2 8.7 10.1 15.0 90.2 7.9 9.0 2.1 1.0	Page Inds	Buy	18,789	19,600	4	238.7	294.7	398.4	78.7	63.8	31.5	25.2	40.0	39.6	43.1
P&G Hygiene Neutral 8,393 8,800 5 13.2 151.6 17.0 6.11 54.4 39.5 32.8 39.3 64.9 62.7 Prabha Dairy Not Rated 133 - 3.5 3.5 6.4 37.6 38.2 1.9 1.8 5.2 4.9 8.2 United Bryw Neutral 2,624 2,525 .4 2.6.7 34.5 51.5 98.2 76.1 1.9.7 1.3.7 2.1.3 1.8.0 2.0.2 2.9. Aggregate - - 1.6 2.0.5 7.5.5 91.6 2.3.8 4.6 2.1 1.4 4.4 3.0.1 1.0 2.4 2.0. 1.0 2.4 2.0.1 2.0.4 5.0 1.1 1.4 2.0.2 1.0.4 2.0.2 1.0.1 3.0.4 1.0.2 1.7 1.4.8 3.9 1.2.0 1.0.1 1.0.4 1.0.3 1.0.1 1.0.1 1.0.1 1.0.1 1.0.1 1.0.1 1.0.1	Parag Milk	Neutral	249	245	-1	3.6	9.1	12.5	68.9	27.3	3.2	2.8	6.0	11.0	13.3
Prabhat Inity Not Rated 133 - 3.5 3.5 6.4 37.6 38.2 1.9 1.8 5.2 4.9 8.4 United Spiret Neutral 77.4 87.5 1.2 8.7 0.1 15.0 90.2 7.9 9.0 1.8 5.2 1.0	Pidilite Ind.	Neutral	838	810	-3	16.7	18.1	20.6	50.1	46.4	13.0	10.6	28.2	25.2	23.5
United Brew Neutral 784 875 12 8.7 10.1 15.0 90.2 77.9 90 8.2 10.1 11.0 14.0 <	P&G Hygiene	Neutral	8,393	8,800	5	132.9	151.6	176.0	63.1	55.4	39.5	32.8	39.3	64.9	62.8
United Spirits Neutral 2,624 2,525 .4 26.7 34.5 51.5 98.2 7.6 13.7 13.7 21.3 18.0 20. Aggregate - 7.6 43.0 13.1 12.1 27.5 28.2 28.3 24.6 5.1 4.4 28.4	Prabhat Dairy	Not Rated	133	-		3.5	3.5	6.4	37.6	38.2	1.9	1.8	5.2	4.9	8.5
Aggregate 47.6 43.0 13.1 12.1 27.5 28.2 29. Healthcare Alembic Phar Neutral 503 510 1 21.6 20.5 25.5 23.3 24.6 5.0 4.4 23.0 19.0 20. Alembic Phar Neutral 1.801 1.830 2 75.7 73.5 91.6 23.8 24.5 5.1 4.4 23.4 19.0 20. Alara Pharma Buy 7.66 850 11 39.3 44.9 50.0 15.1 1.4 8.8 27.6 24.8 22. Biocon Sell 344 330 -4 10.2 9.7 14.2 13.8 26.9 7.1 5.9 23.0 23.9 23.0 23.9 23.0 13.0 24.7 21.6 10.0 PCA 13.0 24.7 14.1 13.3 3.2 12.2 12.1 13.0 24.7 24.6 23.5 14.4 16.3 <	United Brew	Neutral	784	875	12	8.7	10.1	15.0	90.2	77.9	9.0	8.2	10.4	11.0	14.7
Healthcare Neutral 503 510 1 21.6 20.5 25.5 23.3 24.6 5.0 4.4 23.0 19.0 20.0 Akem Lab<	United Spirits	Neutral	2,624	2,525	-4	26.7	34.5	51.5	98.2	76.1	19.7	13.7	21.3	18.0	20.3
Alembic Phar Neutral 503 510 1 21.6 20.5 25.5 23.3 24.6 5.0 4.4 23.0 19.0 20.0 Alkem lab Neutral 1,801 1,830 2 75.7 73.5 91.6 23.8 24.6 5.0 4.4 23.4 19.0 20.0 Alaro Pharma Buy 766 850 11 39.3 44.9 50.0 19.5 7.1 4.8 3.8 27.6 24.8 22.2 Blocon Sell 344 30 -4 10.2 9.7 14.2 33.8 26.9 7.1 5.9 23.0 29.9 25.0 29.9 7.0 14.1 13.0 21.1 13.0 24.5 23.5 18.1 11.9 12.1 14.0 13.0 24.7 16.0 14.4 11.3 2.1 14.1 13.2 2.0 9.7 16.3 3.0 24.7 16.0 14.4 11.3 2.1 14.5 13.3 2.2 2.1 17.7 18.8 3.0 24.7 16.0 17.7	Aggregate								47.6	43.0	13.1	12.1	27.5	28.2	29.3
Alkem Lab Neutral 1,801 1,830 2 75.7 73.5 91.6 23.8 24.5 5.1 4.4 23.4 19.2 20. Ajanta Pharma Buy 1,232 1,666 30 58.4 52.8 64.2 21.1 23.4 4.4 23.6 4.8 22.1 23.4 4.8 27.6 28.7 Biocon Sell 34.4 330 -4 10.2 9.7 14.2 33.8 35.4 4.3 3.9 12.3 11.1 14. Calla Neutral 555 15 14.2 17.9 24.1 33.8 26.9 1.7 5.9 23.0 20.2 12.1 13. Divis Lab Neutral 250 2.60 7 7.6 19.0 10.0 11.1 11.3 1.3 2.0 2.5 1.4 1.8 1.3 2.2 1.6 1.4 1.3 2.2 1.7 1.8 3.0 2.4 2.1 1.7 1.8 Drivis Lab Neutral 2.30 1.5 7.0 2.5 <td>Healthcare</td> <td></td>	Healthcare														
Ajanta Pharma Buy 1,232 1,666 30 58.4 52.8 64.2 21.1 23.4 7.0 5.6 37.7 26.5 25. Aurobindo Buy 766 850 11 39.3 44.9 50.0 19.5 7.1 4.8 3.8 32.6 3.9 12.3 13.1 14.1 Cadila Buy 481 555 15 14.2 17.9 24.1 33.8 26.9 7.1 5.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 23.9 23.0 2	Alembic Phar	Neutral	503	510	1	21.6	20.5	25.5	23.3	24.6	5.0	4.4	23.0	19.0	20.4
Aurobindo Buy 766 850 11 39.3 44.9 50.0 19.5 17.1 4.8 3.8 27.6 24.8 22. Biocon Sell 344 330 -4 10.2 9.7 14.2 33.8 26.9 7.1 5.9 23.0 23.9 26.0 Cipla Neutral 565 520 -8 15.9 21.1 26.0 35.5 26.8 3.6 3.2 10.2 23.5 18.1 19. Divis lab Neutral 22.50 2.400 7 77.6 79.6 12.01 31.0 28.3 3.0 2.9 9.7 10.6 14.1 Genmark Neutral 2.250 2.400 7 7.2 8.2 11.5 17.1 14.4 18.3 3.0 2.9 9.7 10.6 14.1 13.2 12.1 14.1 3.8 3.0 2.9 9.7 10.6 14.4 15.3 14.4 15.3 14.4 15.3 14.1 15.8 14.2 15.3 12.1 14.5 3.0	Alkem Lab	Neutral	1,801	1,830	2	75.7	73.5	91.6	23.8	24.5	5.1	4.4	23.4	19.2	20.5
Biocon Sell 344 330 -4 10.2 9,7 14.2 33.8 35.4 4.3 3.9 12.3 11.1 14. Cadia Buy 481 555 15 14.2 17,9 24.1 33.8 35.5 26.8 3.0 2.1 2.0 2.3 11.1 14. Cadia Neutral 650 52.0 8 15.9 21.1 26.0 27.0 23.0 23.0 2.9 2.0 2.3 18.1 19. Dr Reddy's Neutral 600 7.2 23.7 33.6 40.0 21.9 4.5 4.5 23.5 18.1 19. Granules Buy 152 22.0 45 10.3 2.2 5.6 4.1 1.4 1.8 3.0 2.4 2.1 4.6 Granules Buy 125 200 60 7.2 8.2 11.5 17.1 14.5 3.0 2.4 2.3 8.6 8.2 12.5 Jubiant Life Buy 10.0 1.125 12.8<	Ajanta Pharma	Buy	1,232	1,606	30	58.4	52.8	64.2	21.1	23.4	7.0	5.6	37.7	26.5	25.9
Cadila Buy 481 555 15 14.2 17.9 24.1 33.8 26.9 7.1 5.9 23.0 23.9 26. Cipla Neutral 565 520 -8 15.9 21.1 26.0 35.5 26.8 3.6 3.2 10.2 12.1 13.0 Divis Lab Neutral 2.250 2.400 7 72.6 79.6 120.1 31.0 28.3 3.0 2.9 7.0 10.6 14. Fortis Health Buy 152 220 45 10.3 2.2 5.6 14.7 69.4 1.6 1.4 11.3 2.1 4.9 Glenmark Neutral 2.381 2.500 5 34.4 46.8 54.9 69.3 50.9 10.0 11.7 14.5 23.0 3.0 24.7 21.6 20.0 30.9 10.0 11.7 14.5 23.0 3.0 24.7 21.8 19.5 19.1 Lupin Lupin 14.7 4.0 2.0 10.1 14.1 4.0 17.0 10	Aurobindo	Buy	766	850	11	39.3	44.9	50.0	19.5	17.1	4.8	3.8	27.6	24.8	22.1
Cipla Neutral 565 520 -8 15.9 21.1 26.0 35.5 26.8 3.6 3.2 10.2 12.1 13. Divis Lab Neutral 870 660 -22 39.7 33.6 40.0 21.9 25.9 4.9 4.5 23.5 18.1 19.1 Dr Reddy's Neutral 2,250 2,400 7 72.6 79.6 120.1 31.0 28.3 3.0 2.9 9.7 10.6 14. Fortis Health Buy 152 220 60 7.2 8.2 11.5 17.3 15.3 3.2 2.2 11.4 14.5 23.0 30.0 Granules Buy 125 200 60 7.2 8.2 11.5 17.3 3.2 2.2 11.1 14.5 23.0 30.0 30.3 15.0 3.2 2.7 18.1 19.5 32.0 30.0 31.4 30.3 50.9 10.0 11.7	Biocon	Sell	344	330	-4	10.2	9.7	14.2	33.8	35.4	4.3	3.9	12.3	11.1	14.5
Divis Lab Neutral 870 680 -22 39.7 33.6 40.0 21.9 25.9 4.9 4.5 23.5 18.1 19. Dr Reddy's Neutral 2,250 2,400 7 72.6 79.6 120.1 31.0 28.3 3.0 2.9 9.7 10.6 14. Fortis Health Buy 152 220 45 10.3 2.2 5.6 14.7 69.4 1.6 1.4 11.3 2.1 4.5 Gamark Neutral 2.381 2.500 5 34.4 46.8 54.9 69.3 50.9 10.0 11.7 14.5 2.30. 30. Jublant Life Buy 707 905 28 37.0 47.1 56.7 19.1 15.0 3.2 2.7 18.1 19.5 19. Lupin Buy 1,004 1,125 12 55.8 41.4 56.3 18.0 24.2 3.4 3.0 25.4 <td>Cadila</td> <td>Buy</td> <td>481</td> <td>555</td> <td>15</td> <td>14.2</td> <td>17.9</td> <td>24.1</td> <td>33.8</td> <td>26.9</td> <td>7.1</td> <td>5.9</td> <td>23.0</td> <td>23.9</td> <td>26.3</td>	Cadila	Buy	481	555	15	14.2	17.9	24.1	33.8	26.9	7.1	5.9	23.0	23.9	26.3
Dr Reddy's Neutral 2,250 2,400 7 72.6 79.6 120.1 31.0 28.3 3.0 2.9 9.7 10.6 14. Fortis Health Buy 152 220 45 10.3 2.2 5.6 14.7 69.4 1.6 1.4 11.3 2.1 4.2 Glenmark Neutral 0.64 775 2.8 31.5 1.7.3 15.3 3.2 2.2 2.1 1.7.7 1.8 GSK Pharma Neutral 2.381 2.500 5 34.4 46.8 54.9 69.3 50.9 10.0 1.1.7 1.4.5 2.3.0 30. Jublant Life Buy 707 905 2.8 37.0 47.1 56.7 19.1 15.0 3.2 2.7 18.1 19.5 19.2 Jublant Life Buy 1,004 1,125 12.58 41.4 15.0 32.2 2.9 10.7 14.6 18.0 Shipa Medica	Cipla	Neutral	565	520	-8	15.9	21.1	26.0	35.5	26.8	3.6	3.2	10.2	12.1	13.2
Fortis Health Buy 152 220 45 10.3 2.2 5.6 14.7 69.4 1.6 1.4 11.3 2.1 4.4 Glenmark Neutral 604 775 28 39.3 42.9 51.7 15.4 14.1 1.3 2.1 1.6 1.0 Granules Buy 125 200 60 7.2 8.2 11.5 17.3 15.3 3.2 2.2 2.1 17.7 18.6 GSK Pharma Neutral 2.381 2.500 5 34.4 46.8 54.9 69.3 50.9 10.0 1.7 14.5 23.0 30.0 IPCA Labs Neutral 4.76 430 -10 16.1 16.6 26.8 29.6 28.7 2.4 2.3 8.6 8.2 12.0 Jubiant Life Buy 70.7 905 28 37.0 47.1 56.7 19.1 15.0 32.2 2.7 18.1 19.5 19.1 Lupin Buy 505 805 42 14.4 0.	Divis Lab	Neutral	870	680	-22	39.7	33.6	40.0	21.9	25.9	4.9	4.5	23.5	18.1	19.4
Glenmark Neutral 604 775 28 39.3 42.9 51.7 15.4 14.1 3.8 3.0 24.7 21.6 20. Granules Buy 125 200 60 7.2 8.2 11.5 17.3 15.3 3.2 2.2 21.1 17.7 18. GSK Pharma Neutral 2,381 2,500 5 34.4 46.8 54.9 69.3 50.9 10.0 11.7 14.5 23.0 30. IPCA Labs Neutral 707 905 2.8 37.0 47.1 56.7 19.1 15.0 3.2 2.7 18.1 19.5 19. Lupin Buy 1,004 1,125 12 55.8 41.4 56.3 18.0 24.2 2.4 14.17.0 20.0 Sanofi India Buy 524 515 -2 2.6.1 15.1 23.3 2.0.1 34.8 3.4 3.5 18.5 10.0 14. Syngene Intl Not Rated 47.6 - 13.0 16.1 18.0	Dr Reddy's	Neutral	2,250	2,400	7	72.6	79.6	120.1	31.0	28.3	3.0	2.9	9.7	10.6	14.3
Granules Buy 125 200 60 7.2 8.2 11.5 17.3 15.3 3.2 2.2 21.1 17.7 18. GSK Pharma Neutral 2,381 2,500 5 34.4 46.8 54.9 69.3 50.9 10.0 11.7 14.5 23.0 30. IPCA Labs Neutral 476 430 -10 16.1 16.6 26.8 29.6 28.7 2.4 2.3 8.6 8.2 12. Jublant Life Buy 707 905 28 37.0 47.1 56.7 19.1 15.0 3.2 2.7 18.1 19.5 19. Jublant Life Buy 1,004 1,125 12 55.8 41.4 56.3 18.0 24.2 3.4 3.0 2.6 13.2 16.6 18.3 Shilpa Medicare Buy 565 805 42 14.0 21.1 30.4 40.3 24.8 3.4 3.5 16.0 14.7 20. Sun Pharma Buy 524 515	Fortis Health	Buy	152	220	45	10.3	2.2	5.6	14.7	69.4	1.6	1.4	11.3	2.1	4.9
GSK Pharma Neutral 2,381 2,500 5 34.4 46.8 54.9 69.3 50.9 10.0 11.7 14.5 23.0 30. IPCA Labs Neutral 476 430 -10 16.1 16.6 26.8 29.6 28.7 2.4 2.3 8.6 8.2 12. Jublant Life Buy 707 905 28 37.0 47.1 56.7 19.1 15.0 3.2 2.7 18.1 19.5 19. Lupin Buy 1,004 1,125 122 55.8 41.4 56.3 18.0 24.2 3.4 3.0 20.6 13.2 16. Sanofi India Buy 4,051 4,820 19 129.1 13.36 160.6 31.4 30.3 5.4 5.0 17.1 16.6 18. Syngene Int Not Rated 476 - 13.0 16.1 18.0 36.4 16.9 14.0 16. <t< td=""><td>Glenmark</td><td>Neutral</td><td>604</td><td>775</td><td>28</td><td>39.3</td><td>42.9</td><td>51.7</td><td>15.4</td><td>14.1</td><td>3.8</td><td>3.0</td><td>24.7</td><td>21.6</td><td>20.9</td></t<>	Glenmark	Neutral	604	775	28	39.3	42.9	51.7	15.4	14.1	3.8	3.0	24.7	21.6	20.9
IPCA Labs Neutral 476 430 -10 16.1 16.6 26.8 29.6 28.7 2.4 2.3 8.6 8.2 12. Jubilant Life Buy 707 905 28 37.0 47.1 56.7 19.1 15.0 3.2 2.7 18.1 19.5 19. Lupin Buy 1,004 1,125 12 55.8 41.4 56.6 31.4 30.3 5.4 5.0 17.1 16.6 18. Shilpa Medicare Buy 565 805 42 14.0 21.1 30.4 40.3 2.6.8 49 4.2 14.4 17.0 20. Sun Pharma Buy 524 515 -2 26.1 15.1 23.3 20.1 34.8 3.4 3.5 18.5 10.0 14.7 Syngene Intl Not Rated 476 - 13.0 16.1 18.0 3.6 2.9.7 7.4 6.0 22.2 2.2.5 2.0. 1.0 14.4 17.0 20. 23.4 25.6 4.0	Granules	Buy	125	200	60	7.2	8.2	11.5	17.3	15.3	3.2	2.2	21.1	17.7	18.8
Jubilant Life Buy 707 905 28 37.0 47.1 56.7 19.1 15.0 3.2 2.7 18.1 19.5 19. Lupin Buy 1,004 1,125 12 55.8 41.4 56.3 18.0 24.2 3.4 3.0 20.6 13.2 16. Sanofi India Buy 4,051 4,820 19 129.1 133.6 160.6 31.4 30.3 5.4 5.0 17.1 16.6 18. Shilpa Medicare Buy 565 805 42 14.0 21.1 30.4 40.3 26.8 4.9 4.2 14.4 17.0 20. Strides Shasun Buy 524 515 -2 26.1 15.1 23.3 20.1 34.8 3.4 3.5 18.5 10.0 14.4 Syngene Intl Not Rated 476 - 13.0 16.1 18.0 36.5 29.5 7.4 6.0 22.2 22.5 20. Torrent Pharma Neutral 1,213 11 55.5	GSK Pharma	Neutral	2,381	2,500	5	34.4	46.8	54.9	69.3	50.9	10.0	11.7	14.5	23.0	30.9
Lupin Buy 1,004 1,125 12 55.8 41.4 56.3 18.0 24.2 3.4 3.0 20.6 13.2 16. Sanofi India Buy 4,051 4,820 19 129.1 133.6 160.6 31.4 30.3 5.4 5.0 17.1 16.6 18. Shilpa Medicare Buy 565 805 42 14.0 21.1 30.4 40.3 26.8 4.9 4.2 14.4 17.0 20. Strides Shasun Buy 981 1,300 33 32.3 47.4 74.8 30.4 20.7 3.2 2.9 10.7 14.7 20. Sun Pharma Buy 524 515 -2 26.1 15.1 23.3 20.1 34.8 3.4 3.5 18.0 14.0 14. Syngene Intl Not Rated 1,218 1,350 11 55.2 53.4 67.3 22.1 22.8 4.7 4.2	IPCA Labs	Neutral	476	430	-10	16.1	16.6	26.8	29.6	28.7	2.4	2.3	8.6	8.2	12.2
Sanofi India Buy 4,051 4,820 19 129.1 133.6 160.6 31.4 30.3 5.4 5.0 17.1 16.6 18. Shilpa Medicare Buy 565 805 42 14.0 21.1 30.4 40.3 26.8 4.9 4.2 14.4 17.0 20. Strides Shasun Buy 981 1,300 33 32.3 47.4 74.8 30.4 20.7 3.2 2.9 10.7 14.7 20. Sun Pharma Buy 524 515 -2 26.1 15.1 23.3 20.1 34.8 3.4 3.5 18.5 10.0 14. Syngene Intl Not Rated 476 - 13.0 16.1 18.0 36.5 29.5 7.4 6.0 22.2 22.5 20. Torrent Pharma Neutral 1,218 1,350 11 55.2 53.4 67.3 22.1 22.8 4.7 4.2 23.8 19.5 11. Aggregate	Jubilant Life	Buy	707	905	28	37.0	47.1	56.7	19.1	15.0	3.2	2.7	18.1	19.5	19.6
Sanofi India Buy 4,051 4,820 19 129.1 133.6 160.6 31.4 30.3 5.4 5.0 17.1 16.6 18. Shilpa Medicare Buy 565 805 42 14.0 21.1 30.4 40.3 26.8 4.9 4.2 14.4 17.0 20. Strides Shasun Buy 981 1,300 33 32.3 47.4 74.8 30.4 20.7 3.2 2.9 10.7 14.7 20. Sun Pharma Buy 524 515 -2 26.1 15.1 23.3 20.1 34.8 3.4 3.5 18.5 10.0 14. Syngene Intl Not Rated 476 - 13.0 16.1 18.0 36.5 29.5 7.4 6.0 22.2 22.5 20. Torrent Pharma Neutral 1,218 1,350 11 55.2 53.4 67.3 22.1 22.8 4.7 4.2 23.8 19.5 11. Aggregate	Lupin	Buy	1,004	1,125	12	55.8	41.4	56.3	18.0	24.2	3.4	3.0	20.6	13.2	16.0
Strides Shasun Buy 981 1,300 33 32.3 47.4 74.8 30.4 20.7 3.2 2.9 10.7 14.7 20. Sun Pharma Buy 524 515 -2 26.1 15.1 23.3 20.1 34.8 3.4 3.5 18.5 10.0 14. Syngene Intl Not Rated 476 - 13.0 16.1 18.0 36.5 29.5 7.4 6.0 22.2 22.2 22.0 20. Torrent Pharma Neutral 1,218 1,350 11 55.2 53.4 67.3 22.1 22.8 4.7 4.2 23.8 19.5 21. Aggregate 23.4 25.6 4.0 3.6 16.9 14.0 16. Logistics Buy 171 212 24 9.8 11.2 13.3 17.4 15.3 2.6 2.3 12.6 16.0 16. Blue Dart Not Rated 4,206 - 102.5 12.9 16.32 41.0 32.4 18.2 13.9		Buy	4,051	4,820	19	129.1	133.6	160.6	31.4	30.3	5.4	5.0	17.1	16.6	18.1
Sun Pharma Buy 524 515 -2 26.1 15.1 23.3 20.1 34.8 3.4 3.5 18.5 10.0 14. Syngene Intl Not Rated 476 - 13.0 16.1 18.0 36.5 29.5 7.4 6.0 22.2 22.5 20. Torrent Pharma Neutral 1,218 1,350 11 55.2 53.4 67.3 22.1 22.8 4.7 4.2 23.8 19.5 21. Aggregate 23.4 25.6 4.0 3.6 16.9 14.0 16. Logistics U 171 212 24 9.8 11.2 13.3 17.4 15.3 2.6 2.3 12.6 16.0 16. Blue Dart Not Rated 4,206 - 102.5 129.9 163.2 41.0 32.4 18.2 13.9 50.5 48.6 46. Concor Neutral 1,367 1,214 -11 38.0 42.1 48.6 36.0 32.4 3.8 3.6 10.8 <	Shilpa Medicare	Buy	565	805	42	14.0	21.1	30.4	40.3	26.8	4.9	4.2	14.4	17.0	20.4
Syngene Intl Not Rated 476 - 13.0 16.1 18.0 36.5 29.5 7.4 6.0 22.2 22.5 20. Torrent Pharma Neutral 1,218 1,350 11 55.2 53.4 67.3 22.1 22.8 4.7 4.2 23.8 19.5 21. Aggregate 23.4 25.6 4.0 3.6 16.9 14.0 16. Logistics Buy 171 212 24 9.8 11.2 13.3 17.4 15.3 2.6 2.3 12.6 16.0 16. Blue Dart Not Rated 4,206 - 102.5 129.9 163.2 41.0 32.4 18.2 13.9 50.5 48.6 46. Concor Neutral 1,367 1,214 -11 38.0 42.1 48.6 36.0 32.4 3.8 3.6 10.8 11.3 12. Gateway Buy 233 272 17 6.8 9.0 12.4 34.2 25.9 2.5 2.4 7.3 9	Strides Shasun	Buy	981	1,300	33	32.3	47.4	74.8	30.4	20.7	3.2	2.9	10.7	14.7	20.2
Torrent Pharma Neutral 1,218 1,350 11 55.2 53.4 67.3 22.1 22.8 4.7 4.2 23.8 19.5 21. Aggregate 23.4 25.6 4.0 3.6 16.9 14.0 16. Logistics 3.4 25.6 4.0 3.6 16.9 14.0 16. Blue Dart Not Rated 4,206 - 102.5 129.9 163.2 41.0 32.4 18.2 13.9 50.5 48.6 46. Concor Neutral 1,367 1,214 -11 38.0 42.1 48.6 36.0 32.4 3.8 3.6 10.8 11.3 12. Gateway Buy 233 272 17 6.8 9.0 12.4 34.2 25.9 2.5 2.4 7.3 9.4 12. Gati Not Rated 115 - 8.4 15.9 23.9 13.8 7.2 1.9 1.7 12.	Sun Pharma	Buy	524	515	-2	26.1	15.1	23.3	20.1	34.8	3.4	3.5	18.5	10.0	14.7
Aggregate23.425.64.03.616.914.016.LogisticsBuy171212249.811.213.317.415.32.62.312.616.016.Blue DartNot Rated4,206-102.5129.9163.241.032.418.213.950.548.646.ConcorNeutral1,3671,214-1138.042.148.636.032.43.83.610.811.312.Gateway DistriparksBuy233272176.89.012.434.225.92.52.47.39.412.GatiNot Rated115-8.415.923.913.87.21.91.712.419.425.Transport Corp.Not Rated297-16.921.025.917.514.12.72.316.717.818.Aggregate31.526.43.93.612.413.815.15.44.23.825.525.826.Dish TVBuy79106351.01.34.379.660.117.113.324.124.999.D B CorpBuy3664502320.423.727.618.015.44.23.825.525.826.Den Net.Neutral9390-3-8.6-2.70.3NMNM	Syngene Intl	Not Rated	476	-		13.0	16.1	18.0	36.5	29.5	7.4	6.0	22.2	22.5	20.7
Logistics Allcargo Logistics Buy 171 212 24 9.8 11.2 13.3 17.4 15.3 2.6 2.3 12.6 16.0 16. Blue Dart Not Rated 4,206 - 102.5 129.9 163.2 41.0 32.4 18.2 13.9 50.5 48.6 46. Concor Neutral 1,367 1,214 -11 38.0 42.1 48.6 36.0 32.4 3.8 3.6 10.8 11.3 12. Gateway Buy 233 272 17 6.8 9.0 12.4 34.2 25.9 2.5 2.4 7.3 9.4 12. Gati Not Rated 115 - 8.4 15.9 23.9 13.8 7.2 1.9 1.7 12.4 19.4 25. Transport Corp. Not Rated 297 - 16.9 21.0 25.9 17.5 14.1 2.7 2.3 16.7 <	Torrent Pharma	Neutral	1,218	1,350	11	55.2	53.4	67.3	22.1	22.8	4.7	4.2	23.8	19.5	21.5
Logistics Allcargo Logistics Buy 171 212 24 9.8 11.2 13.3 17.4 15.3 2.6 2.3 12.6 16.0 16. Blue Dart Not Rated 4,206 - 102.5 129.9 163.2 41.0 32.4 18.2 13.9 50.5 48.6 46. Concor Neutral 1,367 1,214 -11 38.0 42.1 48.6 36.0 32.4 3.8 3.6 10.8 11.3 12. Gateway Buy 233 272 17 6.8 9.0 12.4 34.2 25.9 2.5 2.4 7.3 9.4 12. Gati Not Rated 115 - 8.4 15.9 23.9 13.8 7.2 1.9 1.7 12.4 19.4 25. Transport Corp. Not Rated 297 - 16.9 21.0 25.9 17.5 14.1 2.7 2.3 16.7 <	Aggregate								23.4	25.6	4.0	3.6	16.9	14.0	16.3
Blue Dart Not Rated 4,206 . 102.5 129.9 163.2 41.0 32.4 18.2 13.9 50.5 48.6 46. Concor Neutral 1,367 1,214 -11 38.0 42.1 48.6 36.0 32.4 3.8 3.6 10.8 11.3 12. Gateway Distriparks Buy 233 272 17 6.8 9.0 12.4 34.2 25.9 2.5 2.4 7.3 9.4 12. Gati Not Rated 115 - 8.4 15.9 23.9 13.8 7.2 1.9 1.7 12.4 19.4 25. Transport Corp. Not Rated 297 - 16.9 21.0 25.9 17.5 14.1 2.7 2.3 16.7 17.8 18. Aggregate 31.5 26.4 3.9 3.6 12.4 13.8 15. Dish TV Buy 79 106 35 1.0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>															
ConcorNeutral1,3671,214-1138.042.148.636.032.43.83.610.811.312.Gateway DistriparksBuy233272176.89.012.434.225.92.52.47.39.412.GatiNot Rated115-8.415.923.913.87.21.91.712.419.425.Transport Corp.Not Rated297-16.921.025.917.514.12.72.316.717.818.Aggregate31.526.43.93.612.413.815.MediaDish TVBuy79106351.01.34.379.660.117.113.324.124.999.D B CorpBuy3664502320.423.727.618.015.44.23.825.525.826.Den Net.Neutral9390-3-8.6-2.70.3NMNM1.71.9-12.0-5.30.7Ent.NetworkNeutral8479281011.413.421.774.163.44.74.46.77.210.Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.4 <td>Allcargo Logistics</td> <td>Buy</td> <td>171</td> <td>212</td> <td>24</td> <td>9.8</td> <td>11.2</td> <td>13.3</td> <td>17.4</td> <td>15.3</td> <td>2.6</td> <td>2.3</td> <td>12.6</td> <td>16.0</td> <td>16.8</td>	Allcargo Logistics	Buy	171	212	24	9.8	11.2	13.3	17.4	15.3	2.6	2.3	12.6	16.0	16.8
Gateway DistriparksBuy233272176.89.012.434.225.92.52.47.39.412.GatiNot Rated115-8.415.923.913.87.21.91.712.419.425.Transport Corp.Not Rated297-16.921.025.917.514.12.72.316.717.818.Aggregate31.526.43.93.612.413.815.MediaDish TVBuy79106351.01.34.379.660.117.113.324.124.999.D B CorpBuy3664502320.423.727.618.015.44.23.825.525.826.8Den Net.Neutral9390-3-8.6-2.70.3NMNM1.71.9-12.0-5.30.7Ent.NetworkNeutral8479281011.413.421.774.163.44.74.46.77.210.Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.47.98.113.112.20.90.87.16.96.4	Blue Dart	Not Rated	4,206	-		102.5	129.9	163.2	41.0	32.4	18.2	13.9	50.5	48.6	46.8
Distriparks Bdy 233 272 17 6.8 9.0 12.4 34.2 25.9 2.5 2.4 7.3 9.4 12.5 Gati Not Rated 115 - 8.4 15.9 23.9 13.8 7.2 1.9 1.7 12.4 19.4 25.5 Transport Corp. Not Rated 297 - 16.9 21.0 25.9 17.5 14.1 2.7 2.3 16.7 17.8 18. Aggregate 31.5 26.4 3.9 3.6 12.4 13.8 15. Media USE 31.5 26.4 3.9 3.6 12.4 13.8 15. Dish TV Buy 79 106 35 1.0 1.3 4.3 79.6 60.1 17.1 13.3 24.1 24.9 99. D B Corp Buy 366 450 23 20.4 23.7 27.6 18.0 15.4 4.2 3.8	Concor	Neutral	1,367	1,214	-11	38.0	42.1	48.6	36.0	32.4	3.8	3.6	10.8	11.3	12.4
Distripans V Gati Not Rated 115 - 8.4 15.9 23.9 13.8 7.2 1.9 1.7 12.4 19.4 25. Transport Corp. Not Rated 297 - 16.9 21.0 25.9 17.5 14.1 2.7 2.3 16.7 17.8 18. Aggregate 31.5 26.4 3.9 3.6 12.4 13.8 15. Media V Buy 79 106 35 1.0 1.3 4.3 79.6 60.1 17.1 13.3 24.1 24.9 99. D B Corp Buy 366 450 23 20.4 23.7 27.6 18.0 15.4 4.2 3.8 25.5 25.8 26.6 26.7 0.3 NM NM 1.7 1.9 -12.0 -5.3 0.7 Den Net. Neutral 93 90 -3 -8.6 -2.7 0.3 NM NM 1.7 1.9 -12.0 -5.3 0.7 Ent.Network Neutral	Gateway	Puw/	222	272	17	6.0	0.0	12 /	21.2	25.0	2 5	2.4	7 2	0.4	12.4
Transport Corp.Not Rated297-16.921.025.917.514.12.72.316.717.818.Aggregate31.526.43.93.612.413.815.MediaDish TVBuy79106351.01.34.379.660.117.113.324.124.999.D B CorpBuy3664502320.423.727.618.015.44.23.825.525.826.Den Net.Neutral9390-3-8.6-2.70.3NMNM1.71.9-12.0-5.30.7Ent.NetworkNeutral8479281011.413.421.774.163.44.74.46.77.210.Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.47.98.113.112.20.90.87.16.96.4				212	17	0.0									
Aggregate31.526.43.93.612.413.815.MediaDish TVBuy79106351.01.34.379.660.117.113.324.124.999.D B CorpBuy3664502320.423.727.618.015.44.23.825.525.826.Den Net.Neutral9390-3-8.6-2.70.3NMNM1.71.9-12.0-5.30.7Ent.NetworkNeutral8479281011.413.421.774.163.44.74.46.77.210.Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.47.98.113.112.20.90.87.16.96.4			115	-										19.4	25.4
Media Dish TV Buy 79 106 35 1.0 1.3 4.3 79.6 60.1 17.1 13.3 24.1 24.9 99. D B Corp Buy 366 450 23 20.4 23.7 27.6 18.0 15.4 4.2 3.8 25.5 25.8 26. Den Net. Neutral 93 90 -3 -8.6 -2.7 0.3 NM NM 1.7 1.9 -12.0 -5.3 0.7 Ent.Network Neutral 847 928 10 11.4 13.4 21.7 74.1 63.4 4.7 4.4 6.7 7.2 10. Hind. Media Buy 260 350 35 25.9 28.3 33.6 10.1 9.2 1.7 1.5 19.0 17.3 17. HT Media Neutral 97 90 -7 7.4 7.9 8.1 13.1 12.2 0.9 0.8	Transport Corp.	Not Rated	297	-		16.9	21.0	25.9		14.1					18.6
Dish TVBuy79106351.01.34.379.660.117.113.324.124.999.D B CorpBuy3664502320.423.727.618.015.44.23.825.525.826.Den Net.Neutral9390-3-8.6-2.70.3NMNM1.71.9-12.0-5.30.7Ent.NetworkNeutral8479281011.413.421.774.163.44.74.46.77.210.Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.47.98.113.112.20.90.87.16.96.4	Aggregate								31.5	26.4	3.9	3.6	12.4	13.8	15.4
D B CorpBuy3664502320.423.727.618.015.44.23.825.525.826.Den Net.Neutral9390-3-8.6-2.70.3NMNM1.71.9-12.0-5.30.7Ent.NetworkNeutral8479281011.413.421.774.163.44.74.46.77.210.Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.47.98.113.112.20.90.87.16.96.4															
Den Net.Neutral9390-3-8.6-2.70.3NMNM1.71.9-12.0-5.30.7Ent.NetworkNeutral8479281011.413.421.774.163.44.74.46.77.210.Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.47.98.113.112.20.90.87.16.96.4		•													99.2
Ent.NetworkNeutral8479281011.413.421.774.163.44.74.46.77.210.Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.47.98.113.112.20.90.87.16.96.4	•	•													26.6
Hind. MediaBuy2603503525.928.333.610.19.21.71.519.017.317.HT MediaNeutral9790-77.47.98.113.112.20.90.87.16.96.4					-3				NM						0.7
HT Media Neutral 97 90 -7 7.4 7.9 8.1 13.1 12.2 0.9 0.8 7.1 6.9 6.4															10.7
		Buy													17.3
Jagran Prak. Buy 181 225 25 10.8 12.4 14.1 16.8 14.6 2.4 2.4 17.6 16.5 17.															6.4
		•													17.4
		Buy						14.0							12.4
		3													18.2
	Siti Not	Moutral	25	22	28	1 0	03	0.4	NIM	NIN/	2 5	3.6	-23 5	_/ 1	6.2
Sun TV Neutral 836 860 3 24.9 28.5 35.9 33.6 29.3 7.9 7.3 23.6 25.0 28.			25									5.0			

		CMP	TP	% Upside		EPS (INF	2)	P/E	(x)	P/	B (x)		ROE (%)	
Company	Reco	(INR)	(INR)	Downside	FY17	FY18E	, FY19E	FY17	FY18E	FY17	FY18E	FY17	FY18E	FY19E
Zee Ent.	Buy	530	630	19	23.1	14.7	18.9	22.9	35.9	8.8	7.6	24.7	22.6	24.5
Aggregate								40.7	31.2	5.7	5.2	14.0	16.7	21.3
Metals														
Hindalco	Buy	247	309	25	16.2	22.0	26.3	15.3	11.3	1.9	1.6	14.0	15.3	15.4
Hind. Zinc	Neutral	304	301	-1	19.7	22.2	29.3	15.5	13.7	4.2	4.5	24.4	31.5	38.0
JSPL	Buy	148	194	31	-20.9	-15.8	2.0	NM	NM	0.4	0.5	-7.9	-4.9	0.6
JSW Steel	Buy	265	297	12	14.8	21.9	25.7	17.9	12.1	2.8	2.4	17.3	21.3	20.8
Nalco	Neutral	81	63	-22	3.7	3.5	4.2	22.0	23.3	1.5	1.5	7.2	6.5	7.7
NMDC	Buy	133	180	36	10.0	12.4	12.1	13.3	10.7	1.9	1.7	12.8	15.2	15.6
SAIL	Sell	62	30	-52	-6.2	-7.7	-4.2	NM	NM	0.7	0.8	-6.7	-9.1	-5.3
Vedanta	Buy	320	361	13	15.1	23.9	37.4	21.1	13.4	2.0	1.8	9.7	14.2	20.4
Tata Steel	Neutral	678	591	-13	37.9	65.1	64.3	17.9	10.4	2.1	1.8	15.7	18.6	16.2
Aggregate								22.0	15.3	1.8	1.7	8.2	11.2	14.0
Oil & Gas														
BPCL	Neutral	501	515	3	48.3	34.3	41.3	10.4	14.6	3.2	2.8	32.4	20.4	21.4
GAIL	Sell	401	346	-14	22.6	26.5	31.3	17.8	15.1	1.8	1.7	9.6	11.3	12.4
Gujarat Gas	Sell	832	691	-17	20.4	37.2	46.1	40.9	22.4	7.0	5.6	17.8	27.6	27.4
Gujarat St. Pet.	Neutral	196	171	-13	8.8	11.1	13.3	22.3	17.6	2.5	2.2	11.6	13.2	14.2
HPCL	Buy	459	510	11	40.7	34.1	36.3	11.3	13.5	3.4	3.0	32.4	23.6	21.7
	Buy	420	458	9	43.0	36.7	40.4	9.8	11.4	1.9	1.7	21.2	16.0	15.8
IGL	Neutral	1,428	1,152	-19	44.0	49.9	56.3	32.5	28.6	6.8	5.8	21.0	21.9	20.9
MRPL	Sell	135	113	-16	14.8	9.4	11.7	9.1	14.3	2.3	2.1	31.4	15.5	17.0
Oil India	Buy	319	316	-1	19.3	27.9	31.1	16.5	11.4	0.9	0.8	5.7	7.5	8.0
ONGC	Buy	159	195	22	16.4	16.5	19.7	9.7	9.7	0.9	0.9	10.1	9.4	10.9
PLNG	Buy	232	274 750	18	11.4 48.3	14.0 57.8	17.9	20.4	16.5	4.3	3.6	23.2	23.7	25.5
Reliance Ind.	Neutral	844	750	-11	48.3	57.8	64.1	17.5 13.1	14.6 13.2	1.8 1.7	1.6 1.6	11.6 13.3	12.3 12.2	12.3 12.7
Aggregate Retail								13.1	13.2	1.7	1.0	13.5	12.2	12.7
Jubilant Food	Sell	1,373	850	-38	10.0	14.8	20.7	137.2	92.7	11.2	10.3	8.2	11.1	14.0
Titan Co.	Neutral	634	565	-11	9.0	10.6	12.6	70.2	59.7	13.3	10.3	20.6	21.3	22.2
Aggregate	Neutrai	004	505		7.0	10.0	12.0	74.5	62.2	12.8	11.7	17.2	18.9	19.6
Technology								71.0	02.2	12.0		17.2	10.7	17.0
Cyient	Buy	511	600	17	30.6	35.4	41.9	16.7	14.4	2.7	2.4	16.2	16.6	17.3
HCL Tech.	Neutral	880	950	8	59.8		65.9	14.7	14.2	3.7	3.3	27.5	24.9	23.8
Hexaware	Neutral	275	250	-9	13.7	15.7	16.5	20.1	17.5	4.9	4.2	26.5	25.7	23.1
Infosys	Buy	892	1,050	18	62.9	62.2	67.2	14.2	14.3	3.0	2.7	22.0	19.6	19.3
KPIT Tech	Neutral	121	140	16	11.9	10.6	13.1	10.2	11.4	1.5	1.4	14.3	13.0	14.2
L&T Infotech	Buy	766	880	15	55.5	60.2	68.0	13.8	12.7	4.8	3.7	40.4	33.0	29.4
Mindtree	Neutral	462	450	-3	24.9	28.7	32.9	18.6	16.1	3.0	3.0	16.8	17.3	20.1
Mphasis	Neutral	603	610	1	38.9	40.3	43.0	15.5	15.0	2.1	2.2	13.2	14.5	16.2
NIIT Tech	Neutral	494	540	9	38.0	42.3	48.7	13.0	11.7	1.7	1.6	13.7	14.4	15.4
Persistent Sys	Buy	621	750	21	37.7	43.3	52.0	16.5	14.3	2.5	2.4	17.0	17.9	20.7
Tata Elxsi	Buy	1,823	1,992	9	56.3	67.4	79.7	32.4	27.1	10.2	8.2	37.1	33.5	32.2
TCS	Neutral	2,485	2,350	-5	133.4	133.6	147.7	18.6	18.6	5.5	5.9	32.6	31.1	33.5
Tech Mah	Buy	441	490	11	30.9	34.0	36.8	14.3	13.0	2.3	2.1	18.4	17.4	16.9
Wipro	Neutral	284	270	-5	16.9	18.1	19.1	16.8	15.7	2.7	2.6	16.9	16.1	16.1
Zensar Tech	Buy	807	950	18	52.1	51.9	70.0	15.5	15.5	2.5	2.2	17.2	15.0	17.9
Aggregate								16.6	16.5	3.8	3.8	22.9	22.8	22.0
Telecom														
Bharti Airtel	Buy	398	490	23	11.1	4.3	6.6	35.8	91.7	2.4	2.3	6.7	2.5	3.8
Bharti Infratel	Buy	370	480	30	14.9	17.9	20.4	24.9	20.6	4.4	3.8	16.2	19.8	19.4
Idea Cellular	Buy	82	110	35	-1.1	-10.9	-11.3	NM	NM	1.2	1.4	-1.6	-17.3	-21.7
Tata Comm	Buy	705	775	10	27.2	8.7	26.1	25.9	81.0	12.6	10.9	132.2	14.5	33.6
Aggregate								37.0	204.9	2.6	2.6	6.9	1.2	2.8
Utiltites														

		CMP	TP	% Upside		EPS (INF	2)	P/E	E (x)	P/	B (x)		ROE (%))
Company	Reco	(INR)	(INR)	Downside	FY17	FY18E	FY19E	FY17	FY18E	FY17	FY18E	FY17	FY18E	FY19E
Coal India	Buy	255	305	20	14.9	19.8	22.0	17.1	12.9	6.5	6.1	37.8	47.6	50.5
CESC	Buy	1,058	1,360	29	51.9	88.9	99.3	20.4	11.9	1.3	1.2	6.5	10.6	10.8
JSW Energy	Sell	78	49	-38	3.8	3.4	2.7	20.4	23.2	1.2	1.2	6.3	5.3	4.2
NTPC	Buy	169	211	25	12.0	13.3	15.7	14.1	12.7	1.4	1.3	10.5	10.9	11.9
Power Grid	Buy	213	262	23	14.2	17.4	20.6	15.0	12.3	2.3	2.0	16.2	17.3	17.8
Tata Power	Sell	85	68	-20	5.2	6.4	6.7	16.5	13.4	2.0	1.8	11.2	13.9	12.1
Aggregate								15.7	12.8	2.3	2.1	14.5	16.4	17.2
Others														
Arvind	Neutral	410	375	-8	12.4	12.9	18.6	33.1	31.7	3.0	2.8	10.3	9.1	12.0
Avenue Supermarts	Neutral	1,089	882	-19	7.7	12.7	17.6	142.0	85.6	17.7	15.5	17.9	19.3	23.0
Bata India	Under Review	720	-		13.5	15.7	19.4	53.3	45.9	7.0	6.3	13.9	14.4	15.8
BSE	Neutral	1,030	1,100	7	41.0	42.2	44.6	25.1	24.4	2.1	2.1	8.3	8.5	7.7
Castrol India	Buy	387	489	26	13.6	13.9	14.0	28.4	27.9	32.1	28.9	115.2	108.9	99.2
Century Ply.	Neutral	252	323	28	8.7	9.8	12.9	29.0	25.6	7.8	6.5	31.1	27.7	29.6
Coromandel Intl	Buy	422	523	24	16.6	24.1	29.0	25.4	17.5	4.3	3.7	17.5	22.5	23.4
Delta Corp	Buy	192	243	26	3.1	5.9	8.1	62.9	32.7	4.8	3.2	8.1	12.5	12.9
Dynamatic Tech	Buy	2,300	3,334	45	67.6	112.9	166.7	34.0	20.4	4.7	3.8	15.1	20.7	24.3
Eveready Inds.	Buy	305	358	17	12.9	13.6	16.3	23.7	22.4	7.7	6.2	37.7	30.8	30.1
Interglobe	Neutral	1,185	1,312	11	46.0	63.9	93.7	25.7	18.5	21.2	18.8	86.2	107.5	137.7
Indo Count	Neutral	123	129	5	13.0	8.9	10.8	9.4	13.8	2.9	2.3	34.8	18.6	18.3
Info Edge	Buy	1,104	1,130	2	15.7	21.8	24.7	70.5	50.8	6.8	6.1	10.2	12.7	13.1
Inox Leisure	Sell	232	240	3	3.3	8.0	12.0	69.7	28.9	4.0	3.6	5.9	12.5	16.2
Jain Irrigation	Under Review	104	-		5.5	7.6	10.0	18.8	13.7	1.6	1.6	8.6	11.7	14.8
Just Dial	Neutral	393	465	18	17.5	18.5	21.1	22.5	21.3	3.0	2.7	14.8	13.4	13.7
Kaveri Seed	Buy	570	738	29	19.1	34.0	41.0	29.9	16.8	3.9	4.1	13.6	23.3	27.4
Kitex Garm.	Buy	236	394	67	18.6	22.1	26.2	12.7	10.7	3.4	2.8	29.8	28.6	27.6
Manpasand	Buy	905	926	2	12.7	20.2	30.9	71.3	44.9	4.5	4.2	7.3	8.5	13.5
MCX	Buy	1,110	1,230	11	24.8	29.4	40.7	44.7	37.8	4.2	3.9	9.9	10.7	13.9
Monsanto	Buy	2,539	3,295	30	86.2	105.1	126.7	29.4	24.2	8.3	7.5	31.6	32.5	34.5
Navneet Education	n Buy	171	215	26	7.8	8.7	10.8	22.0	19.6	5.5	4.7	26.8	26.0	27.4
PI Inds.	Buy	740	894	21	33.4	30.4	35.8	22.2	24.3	6.3	5.2	32.8	23.4	22.9
Piramal Enterp.	Buy	2,910	3,044	5	72.6	104.1	144.6	40.1	27.9	3.8	3.5	9.8	13.0	16.4
SRF	Buy	1,579	1,648	4	85.9	80.2	103.0	18.4	19.7	2.9	2.6	16.6	13.7	16.0
S H Kelkar	Buy	260	298	15	7.2	7.6	9.9	35.9	34.2	4.6	4.2	13.7	12.9	15.2
Symphony	Sell	1,379	1,288	-7	23.7	35.1	42.9	58.3	39.3	21.6	19.1	43.3	51.6	54.5
Trident	Buy	98	114	16	6.6	8.3	10.4	14.9	11.9	1.8	1.6	13.0	14.5	16.1
TTK Prestige	Neutral	6,350	5,281	-17	132.1	137.8	176.1	48.1	46.1	8.7	7.9	19.5	18.0	20.7
V-Guard	Neutral	194	167	-14	3.6	4.5	6.0	54.3	43.4	12.9	10.6	27.4	26.9	28.8
Wonderla	Buy	349	393	13	7.0	11.9	16.0	49.9	29.2	4.6	4.1	9.5	14.8	17.5



MOSL Universe stock performance

Company	1 Day (%)	1M (%)	12M (%)
Automobiles			
Amara Raja	0.4	-3.2	-21.5
Ashok Ley.	-0.2	12.0	38.9
Bajaj Auto	-0.1	3.4	-1.7
Bharat Forge	2.7	6.5	46.4
Bosch	-0.1	-0.8	-4.6
CEAT	0.1	3.9	68.7
Eicher Mot.	-0.5	5.5	41.9
Endurance Tech.	-0.3	1.2	
Escorts	0.5	9.8	89.7
Exide Ind	1.1	6.1	17.2
Hero Moto	0.0	-1.5	8.5
M&M	-1.1	-4.8	-8.7
Mahindra CIE	-1.6	1.1	24.4
Maruti Suzuki	-0.6	6.0	50.5
Tata Motors	3.6	7.5	-28.1
TVS Motor	0.5	15.8	96.6
Banks - Private	0.0	10.0	,0.0
Axis Bank	4.2	5.8	-13.7
DCB Bank	1.0	4.6	56.1
Equitas Hold.	-1.3	5.5	-7.7
Federal Bank	1.3	5.3	58.1
HDFC Bank			45.2
	0.0	4.9	
ICICI Bank	0.7	0.7	19.0
IDFC Bank	3.6	11.6	-5.3
IndusInd	-0.9	6.4	45.1
J&K Bank	-0.7	6.4	2.5
Kotak Mah. Bk	-1.2	2.6	25.0
RBL Bank	-0.4	7.1	78.8
South Indian	-0.5	5.3	33.0
Yes Bank	0.6	4.1	47.8
Banks - PSU			
BOB	1.4	2.5	-13.4
BOI	2.7	5.7	26.3
Canara	1.7	4.6	14.2
IDBI Bk	1.5	8.1	-27.3
Indian Bk	0.2	-3.3	30.4
OBC	1.9	12.6	2.5
PNB	1.6	1.5	2.4
SBI	0.2	-1.5	6.3
Union Bk	1.0	7.3	-4.9
NBFCs			
Bajaj Fin.	0.4	11.9	73.4
Bharat Fin.	0.3	19.0	23.2
Capital First	0.2	9.7	18.5
	0.5	2.4	9.7
Dewan Hsg.	1.3	27.8	94.5
GRUH Fin.	2.6	15.4	71.2
HDFC	-0.3	3.3	27.2
Indiabulls Hsg	-0.2	7.9	59.8
L&T Fin.Holdings	-0.3	17.1	121.3
LIC Hsg Fin	-0.3	0.4	15.5
Manappuram	0.6	22.5	14.1
M&M Fin.	-1.4	2.3	27.0
Muthoot Fin	-1.4	12.2	50.8
PFC	1.8	10.2	9.3
Repco Home	0.9	0.3	-19.3
REC	-1.3	1.1	46.1
STF	1.1	10.6	-7.0
Shriram City Union	-0.9	-2.0	-9.3

Company	1 Day (%)	1M (%)	12M (%)
Capital Goods	3.5.7	· · /	× 7
ABB	2.7	5.6	21.7
Bharat Elec.	-2.5	8.1	59.3
BHEL	3.7	8.7	-6.1
Blue Star	-2.0	11.4	51.7
CG Cons. Elec.	-1.1	-2.5	37.0
CG Power & Inds Sol.	-0.4	5.0	6.7
Cummins	1.4	6.4	3.0
GE T&D	-1.1	4.0	23.5
Havells	0.8	6.1	23.9
K E C Intl	2.2	15.3	160.1
L&T	-0.7	5.9	23.5
Pennar Eng.	-1.3	11.7	-35.0
Siemens	3.5	7.4	10.8
Solar Ind	3.2	6.6	46.1
Suzion Energy	0.0	-1.7	6.5
Thermax	7.3	8.8	17.1
Va Tech Wab.	-0.4	1.4	13.9
Voltas	-0.4	-1.7	44.6
Cement	0.7	1.7	0.77
Ambuja Cem.	-0.5	7.1	7.6
ACC	0.2	3.4	13.9
Birla Corp.	-1.0	-0.3	45.2
Dalmia Bharat	0.4	9.3	56.0
Grasim Inds.	0.4	11.1	56.7
India Cem	3.8	6.3	30.6
J K Cements	-1.6	-0.3	29.1
JK Lakshmi Ce	0.1	1.2	-8.1
Ramco Cem	0.1	10.8	28.9
	-1.9		
Orient Cem		4.0	-22.6
Prism Cem	-0.5	-3.2	0.3
Shree Cem	0.2	7.3	11.7
Ultratech	0.7	5.9	6.5
Consumer	0.(7.0	7 1
Asian Paints	-0.6	7.9	7.1
Britannia	0.4	4.0	22.9
Colgate	-0.3	9.1	17.5
Dabur	-0.1	0.2	5.2
Emami	-0.7	2.4	-3.2
Godrej Cons.	-0.3	2.2	13.5
GSK Cons.	0.0	-4.9	-17.4
HUL	-0.3	8.2	37.2
ITC	0.1	0.3	7.9
Jyothy Lab	0.5	8.0	26.7
Marico	-1.9	4.2	14.3
Nestle	0.0	9.2	15.1
Page Inds	1.2	12.6	27.2
Parag Milk	0.0	4.1	-25.9
Pidilite Ind.	0.7	2.9	18.3
P&G Hygiene	1.0	3.3	25.0
Prabhat Dairy	-0.4	1.3	46.1
United Brew	0.4	-1.2	-4.7
United Spirits	-1.2	6.1	13.5
Healthcare			
Alembic Phar	-1.5	-3.1	-20.1
Alkem Lab	0.3	3.3	11.0
Ajanta Pharma	2.7	-0.2	-36.1
Aurobindo	0.9	7.1	-2.1
Biocon	1.6	-1.4	12.0
Cadila	-0.1	-0.9	23.2
Cipla	1.9	-0.9	-2.1





MOSL Universe stock performance

Company	1 Day (%)	1M (%)	12M (%)
Divis Lab	5.0	36.2	-33.6
Dr Reddy's	1.8	12.4	-28.9
Fortis Health	0.3	1.2	-13.2
Glenmark	1.6	-4.2	-32.3
Granules	0.0	7.6	8.5
GSK Pharma	-1.4	-0.7	-19.5
IPCA Labs	-0.3	14.7	-17.6
Jubilant Life	0.2	4.3	26.8
Lupin	1.2	3.7	-34.6
Sanofi India	-0.2	-2.2	-5.5
Shilpa Medicare	-4.1	-2.4	4.9
Strides Shasun	2.6	7.8	-3.5
Sun Pharma	4.2	11.0	-32.8
Syngene Intl	2.0	5.0	-0.8
Torrent Pharma	0.5	0.0	-25.2
Logistics	0.0	0.0	20.2
Allcargo Logistics	-0.4	3.6	-10.6
Blue Dart	0.3	6.8	-22.1
Concor	-0.2	16.8	31.6
	-0.2	-6.2	-14.7
Gateway Distriparks Gati	-0.7	-6.2	-14.7
Transport Corp.	2.2	5.3	61.7
Media	0.(7.0	17.0
Dish TV	-0.6	7.2	-17.8
D B Corp	0.4	-1.3	-8.0
Den Net.	2.9	13.3	29.5
Ent.Network	0.8	5.2	6.7
Hind. Media	0.3	-4.7	-7.0
HT Media	0.4	12.0	18.7
Jagran Prak.	0.8	6.4	-4.4
Music Broadcast	-1.0	8.3	
PVR	-0.1	2.8	12.3
Siti Net.	-2.7	-2.9	-29.3
Sun TV	2.8	11.4	73.9
Zee Ent.	-0.5	2.7	2.1
Metals			
Hindalco	-0.4	7.8	72.5
Hind. Zinc	-0.9	8.3	37.9
JSPL	4.1	8.1	80.7
JSW Steel	0.5	14.0	51.6
Nalco	-1.6	22.3	75.1
NMDC	-0.2	9.8	27.6
SAIL	0.2	6.9	29.0
Vedanta	-2.2	10.5	92.9
Tata Steel	-0.3	9.1	81.3
Oil & Gas			
BPCL	0.1	4.6	30.5
GAIL	-1.7	7.7	38.0
Gujarat Gas	0.0	8.8	35.5
Gujarat St. Pet.	-0.4	6.9	32.6
HPCL	0.3	4.7	72.3
IOC	0.9	0.2	48.4
IGL	2.0	10.1	87.0
MRPL	0.6	11.3	62.8
Oil India	-1.5	13.9	7.1
ONGC	-1.1	-1.5	-3.7
PLNG	-1.1	6.5	38.6
Reliance Ind.	-0.6	7.3	61.5
Retail	-0.0	1.5	01.0
Jubilant Food	3.9	0.6	30.4
Titan Co.	0.5	0.6	52.7
man ou.	0.5	0.5	JZ.1

Company	1 Day (%)	1M (%)	12M (%)
Technology			
Cyient	-2.9	3.8	7.6
HCL Tech.	1.1	2.4	13.5
Hexaware	-0.3	4.0	37.7
Infosys	1.0	-8.9	-14.8
KPIT Tech	-0.4	8.3	-7.1
L&T Infotech	0.3	4.2	19.8
Mindtree	4.2	-1.0	-9.9
Mphasis	-0.1	1.4	16.5
NIIT Tech	-1.4	1.8	20.4
Persistent Sys	0.4	1.5	0.5
Tata Elxsi	0.3	11.0	20.2
TCS	-0.1	0.6	6.7
Tech Mah	0.3	10.0	-5.5
Wipro	-4.1	-1.8	18.8
Zensar Tech	0.4	2.6	-20.9
Telecom			
Bharti Airtel	-0.7	-2.5	24.7
Bharti Infratel	-0.3	-2.5	7.6
Idea Cellular	-1.0	-5.3	-2.3
Tata Comm	3.2	12.1	39.4
Utiltites			
Coal India	-0.4	6.8	-21.4
CESC	1.1	12.3	61.5
JSW Energy	1.8	22.1	-3.5
NTPC	-0.2	-1.9	8.5
Power Grid	-0.2	-4.1	19.0
Tata Power	0.7	7.4	13.5
Others	0.7	7.1	10.0
Arvind	-0.3	10.4	28.7
Avenue Super.	-0.1	20.6	20.7
Bata India	1.2	9.1	36.9
BSE	1.1	3.3	30.7
Castrol India	-0.7	2.2	-12.9
Century Ply.	0.8	-3.6	12.2
Coromandel Intl	-0.2	-0.9	65.1
	-0.2	14.2	20.8
Delta Corp			
Dynamatic Tech	-6.1 -0.1	7.0	-23.7
Eveready Inds.	-0.1	-0.3 -7.5	<u> 10.1</u> 37.4
Interglobe			
Indo Count	-0.7	8.8	-21.2
Info Edge	7.2	13.2	30.9
Inox Leisure	-0.9	-5.6	-14.7
Jain Irrigation	-0.8	9.7	10.0
Just Dial	0.8	13.3	-15.4
Kaveri Seed	-0.1	6.6	61.9
Kitex Garm.	1.2	1.9	-28.9
Manpasand	1.4	12.7	28.6
MCX	-0.9	4.8	16.5
Monsanto	0.0	2.2	-1.3
Navneet Educat.	1.3	10.9	64.2
PI Inds.	-0.9	3.7	-9.0
Piramal Enterp.	5.6	5.4	55.4
SRF	0.7	7.7	-4.5
S H Kelkar	-1.6	0.3	-16.0
Symphony	-1.7	11.8	16.3
Trident	1.0	29.0	97.2
TTK Prestige	0.1	1.2	30.7
V-Guard	0.2	7.1	49.6
Wonderla	-1.1	3.2	-13.6

THEMATIC/STRATEGY RESEARCH GALLERY






















REPORT GALLERY


RECENT INITIATING COVERAGE REPORTS









<image><image>









Prepared, Equipped and Armed





DIFFERENTIATED PRODUCT GALLERY







Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Securities Ltd. (MOSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOSL is a subsidiary company of Motilal Oswal Financial Service Ltd. (MOFSL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Metropolitan Stock Exchange Of India Ltd. (MSE) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) & National Securities Depository Limited (NSDL) and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products. Details of associate entities of Motilal Oswal Securities Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

Pending Regulatory Enquiries against Motilal Oswal Securities Limited by SEBI:

SEBI pursuant to a complaint from client Shri C.R. Mohanraj alleging unauthorized trading, issued a letter dated 29th April 2014 to MOSL notifying appointment of an Adjudicating Officer as per SEBI regulations to hold inquiry and adjudge violation of SEBI Regulations; MOSL requested SEBI to provide all documents, records, investigation report relied upon by SEBI which were referred in Show Cause Notice and also sought personal hearing. The matter is currently pending.

MOSL, it's associates, Research Analyst or their relative may have any financial interest in the subject company. MOSL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. MOSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. MOSL and/or its associates may have received any compensation from the subject company in the past 12 months.

In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, MOSL or any of its associates may have: a) managed or co-managed public offering of securities from subject company of this research report,

- b)
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. c)
- d) Subject Company may have been a client of MOSL or its associates during twelve months preceding the date of distribution of the research report.

MOSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. To enhance transparency, MOSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Terms & Conditions:

This report has been prepared by MOSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOSL will not treat recipients as customers by virtue of their receiving this report. Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Companies where there is interest No

S Analyst ownership of the stock

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

For U.S. Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account

For Singapore

Motifial Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motifial Oswal Securities Limited in India. This research is distributed in Singapore by Motifial Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited:

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not subtable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 3080 1000. Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-30801085.

Registration details of group entities.: MOSL: NSE (Cash): INB231041238; NSE (F&O): INF231041238; NSE (CD): INE231041238; BSE (Cash): INB011041257; BSE(F&O): INF011041257; BSE(Cash): INB261041231; MSE(F&O): INFC 1041231; INFC 1041231; INFC 201041231; INFC 201041236; INFC 1041236; INFC 1041236; INFC 1041237; IN